An unassuming painkiller that most people have in their cupboard could help prevent the spread of cancer. Experts might have ...

The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer ...

Daiichi Sankyo and AstraZeneca’s Enhertu has been recommended for approval in the European Union as a monotherapy for the treatment of adult patients with unresectable or metast ...

AstraZeneca (AZN) and Daiichi Sankyo’s (DSNKY) trastuzumab deruxtecan has been recommended for approval in the European Union as a monotherapy ...

Enhertu is approved for HR-positive, HER2-low or -ultralow metastatic breast cancer, expanding treatment options for these patients. DESTINY-Breast06 trial showed Enhertu reduced disease progression ...

Why do certain logos stick with us longer than our oldest friends, while others fade faster than last season's fashion trends? It's more than nostalgia speaking. These vintage logos – they were more ...

AstraZeneca’s Enhertu (trastuzumab deruxtecan) emerged as the highest-selling new drug in India in 2024, generating Rs 58 crore in its first year, according to IQVIA data. The oncology drug’s ...

Enhertu, an oncology drug by AstraZeneca, led new drug sales in 2024 with Rs 58 crore, reflecting rising cancer cases. Over 3,100 new brands collectively earned Rs 1,097 crore, with significant ...

All patients with breast cancer who may be candidates for antibody-drug conjugate therapy should undergo HER2 testing to determine eligibility for Enhertu (fam-trastuzumab deruxtecan-nxki) — an agent ...

While this quantity is not enough to make them HER2-positive, it is enough to get them a significant benefit from new treatments such as Enhertu. Enhertu is an antibody-drug conjugate. The antibody ...

In the HER2-low population, treatment with trastuzumab deruxtecan reduced the risk of disease progression or death by 38% compared with chemotherapy. The Food and Drug Administration (FDA) has ...